Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6461937 | 0.84 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL4116338 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL5402416 | 0.76 | PTGDR2 (0.77) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL17503234 | 0.76 | — | — | |
| SCHEMBL17503235 | 0.76 | — | — | |
| SCHEMBL17503249 | 0.76 | — | — | |
| SCHEMBL17503247 | 0.76 | — | — | |
| SCHEMBL17503233 | 0.76 | — | — | |
| SCHEMBL17503212 | 0.73 | PTGDR2 (0.73) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL17503210 | 0.73 | PTGDR2 (0.73) | SMN1; SMN2TSHRLMNANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038070-A1 | Asthma and allergic inflammation modulators | AMGEN INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005007094-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK INC. (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038070-A1 | Asthma and allergic inflammation modulators | TSLP, IL5, LTC4S | SMN1; SMN2 4810/4885TSHR 4616/4885LMNA 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.